Role of WNT signaling morphogenic proteins (sclerostin and β-catenin) in adipogenesis
- 作者: Kulakova A.1, Snimshchikova I.2, Plotnikova M.2
-
隶属关系:
- Bryansk Regional Hospital No. 1
- I. Turgenev Oryol State University
- 期: 卷 23, 编号 2 (2020)
- 页面: 133-138
- 栏目: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/119430
- DOI: https://doi.org/10.46235/1028-7221-326-ROW
- ID: 119430
如何引用文章
全文:
详细
Adipogenesis relies on complex and multi-faceted mechanism, as it is influenced by multiple cues, including the components from the WNT signaling pathway. The search for possible markers of developing metabolic diseases associated with obesity accounted for an interest to study the morphogenic proteins sclerostin and β-catenin. The aim of the study was to evaluate activity of the WNT signaling pathway in obese patients by measuring level of serum sclerostin and β-catenin proteins. Materials and Methods. There were enrolled 32 patients with metabolic syndrome featured with progressive forms of obesity (class I-III) lacking diabetes mellitus. Concentration of serum sclerostin and β-catenin was measured by using enzyme-linked immunosorbent assay. Data were presented as absolute and relative (%) number of patients; arithmetic mean; medians, 1 and 3 quartiles – Ме (Q0.25-Q0.75). In obese patients, serum sclerostin level (260 (230-308.75) pg/ml) was increased by 13.5% compared with healthy individuals (225 (220-230) pg/ml, (p < 0.001)); concentration of serum sclerostin tended to increase depending on obesity class, most in parallel with decreased β-catenin level, being in agreement with previous studies that might be considered as a prognostic criterion for assessing course of pathological process in obesity.
作者简介
A. Kulakova
Bryansk Regional Hospital No. 1
编辑信件的主要联系方式.
Email: Kulakovaas@mail.ru
Kulakova Anastasiia S. - Gastroenterologist
41033, Bryansk, Stanke Dimitrov ave., 86
Phone: 7 (980) 310-12-33
俄罗斯联邦I. Snimshchikova
I. Turgenev Oryol State University
Email: fake@neicon.ru
PhD, MD (Medicine), Professor, Head, Department of Immunology and Specialized Clinical Disciplines, Director of Medical Institute
Oryol
俄罗斯联邦M. Plotnikova
I. Turgenev Oryol State University
Email: fake@neicon.ru
Senior Lecturer, Department of Immunology and Specialized Clinical Disciplines
Oryol
俄罗斯联邦参考
- Amrein K., Amrein S., Drexler C., Dimai H. P., Dobnig H., Pfeifer K., Tomaschitz A., Pieber T.R., Astrid Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J. Clin. Endocrinol. Metab., 2012, Vol. 97, no. 1, pp. 148-154.
- Bodine P.V., Stauffer B., Ponce-de-Leon H., Bhat R.A. A small molecule inhibitor of the WNT antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone, 2009, Vol. 44, no. 6, pp. 1063-1068.
- Burgers T.A., Williams B.O. Regulation of WNT/β-catenin signaling within and from osteocytes. Bone, 2013, Vol. 54, no. 2, pp. 244-249.
- Chen D., Xie R., Shu B., Landay A.L. Wei C. WNT signaling in bone, kidney, intestine, and adipose tissue and inter-organ interaction in aging. Ann. N. Y. Acad. Sci., 2019, Vol. 1442, no. 1, pp. 48-60.
- Christodoulides C., Lagathu C., Sethi J.K., Vidal-Puig A. Adipogenesis and WNT signaling. Trends Endocrinol. Metab., 2009, Vol. 20, no. 1, pp. 16-24.
- Kim S.P., Frey J.L., Li Z., Kushwaha P., Zoch M.L., Tomlinson R.E., Da H., Aja S.M., Noh H.L., Kim J.K., Hussain M., Thorek D.L.J., Wolfgang M.J., Riddle R. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc. Natl. Acad. Sci. USA, 2017, Vol. 114, no. 52, pp. E11238-E11247.
- Klangjareonchai T., Nimitphong H., Saetung S., Bhirommuang N., Samittarucksa R., Sudatip R., Ongphiphadhanakul B. Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int. J. Endocrinol., 2014, Vol. 2014, 261545. doi: 10.1155/2014/261545.
- Krause C., Korchynskyi O., Rooij K., Weidauer S.E., Gorter D.J. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and WNT signaling pathways. Biol. Chem., 2010, Vol. 285, no. 53, pp. 41614-41626.
- Malinauskas T., Aricescu R., Lu W., Siebold C., Jones E.Y. Modular mechanism of WNT signaling inhibition by WNT inhibitory factor 1. Nat. Struct. Mol. Biol., 2011, Vol. 18, no. 8, pp. 886-893.
- Medeiros M.C. Rocha N., Bandeira E., Dantas I., Serum sclerostin, body composition, and sarcopenia in hemodialysis patients with diabetes. Int. J. Nephrol., 2020, Vol. 2020, 4596920. doi: 10.1155/2020/4596920.
- Ng L.F., Kaur P., Bunnag N., Suresh J., Sung I.C.H., Tan Q.H., Gruber J., Tolwinski N.S. WNT signaling in disease. Cells, 2019, Vol. 8, no. 8, pp. 826-857.
- Saito-Diaz K. Chen T.W., Wang X., Thorne C.A., Wallace H.A. The way WNT works: components and mechanism. Growth Factors, 2013, Vol. 31, no. 1, pp. 1-31.
- Urano T., Shiraki M., Ouchi Y., Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease: related markers in Japanese postmenopausal women. J. Clin. Endocrinol. Metab., 2012, Vol. 97, pp. 1473-1477.
- Witte F., Dokas J., Neuendorf F., Mundlos S., Stricker S. Comprehensive expression analysis of all WNT genes and their major secreted antagonists during mouse limb development and cartilage differentiation. Gene Expr. Patterns, 2009, Vol. 9, no. 4, pp. 215-223.
